0001358403-16-000130.txt : 20160106 0001358403-16-000130.hdr.sgml : 20160106 20160106162052 ACCESSION NUMBER: 0001358403-16-000130 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160104 FILED AS OF DATE: 20160106 DATE AS OF CHANGE: 20160106 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BELLICUM PHARMACEUTICALS, INC CENTRAL INDEX KEY: 0001358403 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 201450200 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2130 WEST HOLCOMBE BOULEVARD STREET 2: SUITE 800 CITY: HOUSTON STATE: TX ZIP: 77030 BUSINESS PHONE: (832) 384-1100 MAIL ADDRESS: STREET 1: 2130 WEST HOLCOMBE BOULEVARD STREET 2: SUITE 800 CITY: HOUSTON STATE: TX ZIP: 77030 FORMER COMPANY: FORMER CONFORMED NAME: BELLICUM PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060405 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Moseley Annemarie CENTRAL INDEX KEY: 0001626892 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36783 FILM NUMBER: 161327075 MAIL ADDRESS: STREET 1: C/O BELLICUM PHARMACEUTICALS, INC. STREET 2: 2130 W. HOLCOMBE BLVD., STE. 800 CITY: HOUSTON STATE: TX ZIP: 77030 4 1 wf-form4_145211524242237.xml FORM 4 X0306 4 2016-01-04 0 0001358403 BELLICUM PHARMACEUTICALS, INC BLCM 0001626892 Moseley Annemarie C/O BELLICUM PHARMACEUTICALS, INC. 2130 W. HOLCOMBE BLVD., STE. 800 HOUSTON TX 77030 0 1 0 0 COO/EVP Clinical Development Common Stock 2016-01-04 4 M 0 35000 2.55 A 35251 D Common Stock 2016-01-04 4 S 0 32700 19.0089 D 2551 D Common Stock 2016-01-04 4 S 0 2300 19.9578 D 251 D Employee Stock Option (right to buy) 19.0 2016-01-04 4 A 0 125000 0 A 2026-01-03 Common Stock 125000.0 125000 D Stock Option (right to buy) 2.55 2016-01-04 4 M 0 35000 0 D 2021-11-08 Common Stock 35000.0 18235 D Includes 129 shares acquired under the Issuer's Employee Stock Purchase Plan on December 10, 2015. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 19, 2015. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.71 to $19.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.71 to $20.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. 25% of the shares subject to the stock option vest and become exercisable on January 4, 2017, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. 25% of the shares subject to the stock option vest and became exercisable on November 9, 2012, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. /s/ Annemarie Moseley, Ph.D., M.D. 2016-01-06